[Study on the chemical constituents of Clerodendron philippinum var. simplex].

Objective: To study the chemical constituents of Clerodendron philippinum var. simplex.

Methods: The ethanol extract of Clerodendron philippinum var.

[The role of microRNAs in the pathogenesis of cervical cancer and its relationship to HPV].

A lot of miRNAs have participated in the regulation of numerous biological processes such as cell proliferation, apoptosis, invasion and migration in cervical cancer, and closely associated with prognosis and susceptibility of cervical cancer. The oncogenic proteins E6, E7 and E5 expressed by HPV directly or indirectly lead to the dysregulation of multiple miRNAs such as miR-34a,miR-218, miR-29a and miR-146a, subsequently contribute to the initiation and progression of cervical cancer. In turn, some miRNAs such as miR-203 and miR-125b also play roles in the regulation of HPV DNA duplication.

[Clinical study on needle-pricking therapy for treatment of polycystic ovarial syndrome].

Objective: To probe into the clinical effect of needle-pricking therapy for treatment of polycystic ovarial syndrome.

Methods: One hondred and twenty-one cases of polycystic ovarial syndrome were divided into a needle-pricking therapy group of 61 cases and a medication group of 60 cases with randomized and controlled method. The needle-pricking therapy group were treated by needle-pricking therapy at sacral plexus stimulating points on both sides of the spine and lateral points of Dazhui (CV 14), and the medication group by oral administration of domiphen and intramuscular injection of chorionic gonadotropin (HCG).

Prevention of vertical hepatitis B transmission by hepatitis B immunoglobulin in the third trimester of pregnancy.

Objective: To explore the possible efficacy of using hepatitis B immunoglobulin (HBIG) during the third trimester of pregnancy to prevent intrauterine transmission of hepatitis B virus (HBV).

Methods: Of 469 pregnant women testing positive for hepatitis B surface antigens (HBsAg), 126 had hepatitis B e antigen (HBeAg) and 343 did not.

Results: There were women who declined to be treated with HBIG in these 2 groups.